Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation

Frontiers in Immunology(2024)10.3389/fimmu.2023.1290059Source: DataRank Database

Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation is a research paper published in Frontiers in Immunology (2024). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.90)OA: goldTopics (58)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Susan E. Prockop ORCID,Joseph H. Oved ORCID,Richard J. O’Reilly

Live enrichment

PubMed:38274824 PMC:PMC10808771 OpenAlex:https://openalex.org/W4390743703

NCI NIH HHS

Grant: R21 CA162002

NCI NIH HHS

Grant: P01 CA023766

NCI NIH HHS

Grant: P30 CA008748

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 5P01CA023766-14

MARROW TRANSPLANTATION IN LEUKEMIA AND OTHER DISEASES

National Institutes of Health

Grant: 5R21CA162002-02

EBV Specific T-cells from 3rd party donors for treatment of EBV-associated malign

FWCI

1.90

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1290059/pdf?isPublishedV2=False

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1290059/pdf?isPublishedV2=False

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1290059/full

journalhttps://doi.org/10.3389/fimmu.2023.1290059

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38274824

Fields of Study

CAR-T cell therapy researchImmune Cell Function and InteractionCytomegalovirus and herpesvirus research0301 basic medicine03 medical and health sciences0302 clinical medicineHumansHerpesvirus 4, HumanEpstein-Barr Virus InfectionsRituximabNeoplasm Recurrence, LocalLymphoproliferative DisordersLymphomaT-LymphocytesOrgan TransplantationHematopoietic Stem Cell TransplantationTissue Donors

MeSH Terms

RituximabHerpesvirus 4, HumanHumansLymphomaLymphoproliferative DisordersNeoplasm Recurrence, LocalT-LymphocytesTissue DonorsOrgan TransplantationHematopoietic Stem Cell TransplantationEpstein-Barr Virus Infections

Keywords

RituximabMedicineLymphomaImmunologyTransplantationHematopoietic cellImmune systemSalvage therapySolid organOrgan transplantationHaematopoiesisInternal medicineChemotherapyStem cellBiologyepstein-barr virus (EBV)T-cellsLymphoproliferative DisorderThird PartyEbv-CtlsHerpesvirus 4, HumanEpstein-Barr Virus InfectionsT-LymphocytesHematopoietic Stem Cell TransplantationRC581-607Lymphoproliferative DisordersTissue DonorsHumansImmunologic diseases. AllergyNeoplasm Recurrence, Local

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being